FAGR Stock Overview
Fagron NV, a pharmaceutical compounding company, delivers personalized pharmaceutical care to hospitals, pharmacies, clinics, and patients worldwide.
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 2/6 |
| Past Performance | 3/6 |
| Financial Health | 4/6 |
| Dividends | 2/6 |
Fagron NV Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | €18.92 |
| 52 Week High | €18.94 |
| 52 Week Low | €14.64 |
| Beta | 0.27 |
| 1 Month Change | 11.03% |
| 3 Month Change | 10.90% |
| 1 Year Change | 10.19% |
| 3 Year Change | -1.20% |
| 5 Year Change | 6.23% |
| Change since IPO | 87.88% |
Recent News & Updates
Fagron NV's (EBR:FAGR) CEO Will Probably Find It Hard To See A Huge Raise This Year
May 07
The Returns At Fagron (EBR:FAGR) Aren't Growing
Apr 17Is Fagron (EBR:FAGR) A Risky Investment?
Mar 15Earnings Tell The Story For Fagron NV (EBR:FAGR)
Feb 18Recent updates
Fagron NV's (EBR:FAGR) CEO Will Probably Find It Hard To See A Huge Raise This Year
May 07The Returns At Fagron (EBR:FAGR) Aren't Growing
Apr 17Is Fagron (EBR:FAGR) A Risky Investment?
Mar 15Earnings Tell The Story For Fagron NV (EBR:FAGR)
Feb 18Fagron (EBR:FAGR) Seems To Use Debt Quite Sensibly
Aug 11Be Wary Of Fagron (EBR:FAGR) And Its Returns On Capital
Jun 10Fagron (EBR:FAGR) Has Announced That It Will Be Increasing Its Dividend To €0.175
May 12An Intrinsic Calculation For Fagron NV (EBR:FAGR) Suggests It's 30% Undervalued
Apr 20Is Fagron (EBR:FAGR) A Risky Investment?
Apr 02Here's Why Fagron (EBR:FAGR) Can Manage Its Debt Responsibly
Oct 14Return Trends At Fagron (EBR:FAGR) Aren't Appealing
Jun 04Fagron (EBR:FAGR) Is Paying Out A Larger Dividend Than Last Year
May 13Is Fagron (EBR:FAGR) Using Too Much Debt?
Apr 13Slowing Rates Of Return At Fagron (EBR:FAGR) Leave Little Room For Excitement
Feb 16Fagron (EBR:FAGR) Has A Pretty Healthy Balance Sheet
Nov 18Fagron (EBR:FAGR) Is Experiencing Growth In Returns On Capital
Sep 25Are Investors Undervaluing Fagron NV (EBR:FAGR) By 45%?
Aug 30Fagron NV (EBR:FAGR) Just Reported Half-Year Earnings: Have Analysts Changed Their Mind On The Stock?
Aug 08Is Fagron (EBR:FAGR) A Risky Investment?
Jun 15Fagron NV (EBR:FAGR) Shares Could Be 49% Below Their Intrinsic Value Estimate
May 29The Returns At Fagron (EBR:FAGR) Aren't Growing
May 03Here's Why Fagron (EBR:FAGR) Can Manage Its Debt Responsibly
Mar 08Is Fagron NV (EBR:FAGR) A Smart Choice For Dividend Investors?
Feb 22The Returns At Fagron (EBR:FAGR) Provide Us With Signs Of What's To Come
Jan 31Is Fagron NV (EBR:FAGR) Popular Amongst Institutions?
Jan 14
How Much Does Fagron's (EBR:FAGR) CEO Make?
Dec 27Are Investors Undervaluing Fagron NV (EBR:FAGR) By 25%?
Dec 14Fagron (EBR:FAGR) Seems To Use Debt Quite Sensibly
Nov 30Should You Be Excited About Fagron NV's (EBR:FAGR) 26% Return On Equity?
Nov 17Is Fagron (EBR:FAGR) Using Too Much Debt?
Aug 23Why Fagron NV (EBR:FAGR) Looks Like A Quality Company
Aug 10Should Fagron (EBR:FAGR) Be Disappointed With Their 64% Profit?
Jul 28Will Fagron (EBR:FAGR) Multiply In Value Going Forward?
Jul 14What Kind Of Shareholder Owns Most Fagron NV (EBR:FAGR) Stock?
Jun 30Shareholder Returns
| FAGR | BE Healthcare | BE Market | |
|---|---|---|---|
| 7D | 3.7% | 3.3% | 4.0% |
| 1Y | 10.2% | -4.0% | 2.7% |
Return vs Industry: FAGR exceeded the Belgian Healthcare industry which returned -6.1% over the past year.
Return vs Market: FAGR exceeded the Belgian Market which returned 2% over the past year.
Price Volatility
| FAGR volatility | |
|---|---|
| FAGR Average Weekly Movement | 2.6% |
| Healthcare Industry Average Movement | 4.8% |
| Market Average Movement | 3.8% |
| 10% most volatile stocks in BE Market | 7.8% |
| 10% least volatile stocks in BE Market | 2.5% |
Stable Share Price: FAGR has not had significant price volatility in the past 3 months.
Volatility Over Time: FAGR's weekly volatility (3%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1990 | 3,282 | Rafael Padilla | www.fagron.com |
Fagron NV, a pharmaceutical compounding company, delivers personalized pharmaceutical care to hospitals, pharmacies, clinics, and patients worldwide. It operates in three segments: Essentials, Brands, and Compounding Services. The company also innovates concepts, vehicles, and formulations for pharmaceutical compounding.
Fagron NV Fundamentals Summary
| FAGR fundamental statistics | |
|---|---|
| Market cap | €1.38b |
| Earnings (TTM) | €70.55m |
| Revenue (TTM) | €762.99m |
19.6x
P/E Ratio1.8x
P/S RatioIs FAGR overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| FAGR income statement (TTM) | |
|---|---|
| Revenue | €762.99m |
| Cost of Revenue | €430.38m |
| Gross Profit | €332.61m |
| Other Expenses | €262.07m |
| Earnings | €70.55m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
Aug 01, 2024
| Earnings per share (EPS) | 0.97 |
| Gross Margin | 43.59% |
| Net Profit Margin | 9.25% |
| Debt/Equity Ratio | 69.7% |
How did FAGR perform over the long term?
See historical performance and comparison